Early Economic Evaluation of Single Versus Dual Antiplatelet Therapy After Endovascular Revascularization for Peripheral Artery Disease

This early economic evaluation shows that DAPT will dominate SAPT in patients with PAD after endovascular revascularization at a small decrease in major adverse cardiovascular events and major adverse limb events. At the assumed DAPT probability for major bleeding, a decrease in probability of major bleeding in SAPT patients never outweighs the positive effect of any decrease of major adverse cardiovascular events and major adverse limb events for DAPT patients. DAPT could reduce health care costs and increase quality of life in patients with PAD.